Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomilnacipran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 12/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1R,2S-Milnacipran SCHEMBL30083111 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Levomilnacipran SCHEMBL12027608 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL5504533 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Levomilnacipran SCHEMBL1414867 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL8099 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Milnacipran SCHEMBL114034 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Milnacipran SCHEMBL1156056 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL4434769 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL16241424 | 0.99 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Levomilnacipran SCHEMBL1289763 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012046247-A2 | PROCESS FOR THE PREPARATION OF (±M1R(S), 2SRR)L-2-(AMINOMETHYL)-N,N-DIETHYL-L-PHENYLCYCLOPROPANE CARBOXAMIDE HYDROCHLORIDE | MSN LABORATORIES LIMITED (IN) | 2012-04-12 | — | — | WO | disclosed |
| US-20100274050-A1 | SOLID MILNACIPRAN AND PROCESS FOR THE PREPARATION OF THE SAME | GLENMARK GENERICS LIMITED (IN) | 2010-10-28 | — | — | US | disclosed |
| US-20100274050-A1 | SOLID MILNACIPRAN AND PROCESS FOR THE PREPARATION OF THE SAME | GLENMARK GENERICS LIMITED (IN) | 2010-10-28 | — | — | US | disclosed |
| US-20090227632-A1 | PHARMACEUTICAL COMPOSITION COMPRISING, IN COMBINATION, SAREDUTANT AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR OR A SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITOR | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20080033014-A1 | PHARMACEUTICAL COMPOSITION COMPRISING, IN COMBINATION, SAREDUTANT AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR OR A SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITOR | SANOFI-AVENTIS (FR) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274050-A1 | SOLID MILNACIPRAN AND PROCESS FOR THE PREPARATION OF THE SAME | GCG, AREG, CTSG | SLC6A2 1122/4885SLC6A4 628/4885SLC6A3 1007/4885 |
| US-20080033014-A1 | PHARMACEUTICAL COMPOSITION COMPRISING, IN COMBINATION, SAREDUTANT AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR OR A SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITOR | SLC6A2, SLC6A4, MAOB | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 4/4885 |
| US-20090227632-A1 | PHARMACEUTICAL COMPOSITION COMPRISING, IN COMBINATION, SAREDUTANT AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR OR A SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITOR | SLC6A2, SLC6A4, MAOB | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.